Tech Company Financing Transactions

Antidote Funding Round

Antidote, operating out of New York, secured $11 million in funding from Merck Global Health Innovation Fund, Octopus Investments and Smedvig Capital.

Transaction Overview

Company Name
Antidote
Announced On
9/8/2017
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Undisclosed
Investors

Merck Global Health Innovation Fund (Lead Investor) (Francesca Wuttke)

Octopus Investments (Malcolm Ferguson)

Smedvig Capital (Jordan Mayo)

Proceeds Purpose
This new round of funding, which brings the total investment in Antidote to date up to $26M, will accelerate the development of new capabilities for its trial matching platform, including precision medicine and EHR-matching, as well as further global expansion.

Company Information

Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
450 Park Ave. South 3rd floor
New York, NY 10016
USA
Phone
(888) 509-1308
Website
www.antidote.me
Email Address
[email protected]
Overview
Antidote is a digital health company on a mission. Our aim is to accelerate the breakthroughs of potentially life-saving treatments, by bridging the gap between medical research and the people who need it.
Profile
Antidote LinkedIn Company Profile
Social Media
Antidote Company Twitter Account
Company News
Antidote News
Facebook
Antidote on Facebook
YouTube
Antidote on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Laurent Schockmel
  Laurent Schockmel LinkedIn Profile  Laurent Schockmel Twitter Account  Laurent Schockmel News  Laurent Schockmel on Facebook
Chief Financial Officer
Keith Lovell
  Keith Lovell LinkedIn Profile  Keith Lovell Twitter Account  Keith Lovell News  Keith Lovell on Facebook
Chief Technical Officer
Dean Sellis
  Dean Sellis LinkedIn Profile  Dean Sellis Twitter Account  Dean Sellis News  Dean Sellis on Facebook
VP - Bus. Development
Kathy Freeman
  Kathy Freeman LinkedIn Profile  Kathy Freeman Twitter Account  Kathy Freeman News  Kathy Freeman on Facebook
VP - Bus. Development
Thomas Krohn
  Thomas Krohn LinkedIn Profile  Thomas Krohn Twitter Account  Thomas Krohn News  Thomas Krohn on Facebook
VP - Human Resources
Nicola Yudaken
  Nicola Yudaken LinkedIn Profile  Nicola Yudaken Twitter Account  Nicola Yudaken News  Nicola Yudaken on Facebook
VP - Marketing
Grace McElroy
  Grace McElroy LinkedIn Profile  Grace McElroy Twitter Account  Grace McElroy News  Grace McElroy on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/8/2017: Taunt venture capital transaction
Next: 9/8/2017: Maestro venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.